Research Topics
Species | R P BaughmanSummaryAffiliation: University of Cincinnati Country: USA Publications
| Collaborators
|
Detail Information
Publications
Considerations in the choice and administration of agents for empiric antimicrobial therapyRobert P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
Surg Infect (Larchmt) 6:S-71-82. 2005..The choice of empiric therapy has become increasingly difficult because of the increasing incidence of antibiotic-resistant bacteria...- Endpoints for clinical trials of sarcoidosisR P Baughman
University of Cincinnati Medical Center, Cincinnati, OH, USA
Sarcoidosis Vasc Diffuse Lung Dis 29:90-8. 2012..For example, it was recommended that pulmonary studies should include changes in the forced vital capacity. Additionally, it was recommended that all trials should incorporate measurement of quality of life... 
Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesRobert P Baughman
University of Cincinnati, Cincinnati, OH 45267 0565, USA
Chest 142:e1S-e111S. 2012....- Management of ocular sarcoidosisR P Baughman
Department of Internal Medicine, University of Cincinnati, Cincinnati OH, USA
Sarcoidosis Vasc Diffuse Lung Dis 29:26-33. 2012..A step wise approach to the use of cytotoxic and anti-tumor necrosis factor (TNF) antibodies has been developed for managing chronic sarcoidosis... 
Pulmonary manifestations of sarcoidosisRobert P Baughman
University of Cincinnati, Department of Internal Medicine, 1001, Holmes, Eden Avenue and Albert Sabin Way, Cincinnati, OH 45267, USA
Presse Med 41:e289-302. 2012..Other chest manifestations include adenopathy, pulmonary hypertension, and pulmonary muscle weakness. Fibrotic lung disease can lead to bronchiectasis, which can become infected...- Diagnosis of ventilator-associated pneumoniaRobert P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
Microbes Infect 7:262-7. 2005..The culture results are more meaningful if reported in a semi-quantitative model. There is increasing evidence that culture results predict mortality and can be used to direct duration and type of therapy... - Infliximab in chronic ocular inflammationR P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
Int J Clin Pharmacol Ther 43:7-11. 2005..Infliximab is a chimeric antibody which binds tumor necrosis factor (TNF). It is effective in several chronic inflammatory conditions, including sarcoidosis... - Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agentsRobert P Baughman
Department of Medicine, Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati, Cincinnati, Ohio, USA
Am J Clin Dermatol 5:385-94. 2004..Over the next few years, it is hoped that there will be clinical trials to determine the role of each new therapy in the treatment of cutaneous sarcoidosis... - Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trialRobert P Baughman
Department of Internal Medicine, 1001 Holmes, Eden Ave, University of Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
Chest 128:1062-47. 2005..Study a tumor necrosis factor receptor antagonist (etanercept) in the treatment of chronic ocular sarcoidosis... - Pulmonary sarcoidosisRobert P Baughman
University of Cincinnati Medical Center, 1001 Holmes, Eden Avenue, Cincinnati, OH 45267 0565, USA
Clin Chest Med 25:521-30, vi. 2004..Treatment options include corticosteroids.In the past few years, alternatives to corticosteroids have been developed,especially for patients with a chronic condition... - Leflunomide for chronic sarcoidosisRobert P Baughman
Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati Medical Center, Cincinnati, Ohio, USA
Sarcoidosis Vasc Diffuse Lung Dis 21:43-8. 2004..It appears to have less toxicity than methotrexate. The use of leflunomide for sarcoidosis patients has not been systematically evaluated... - The use of carbapenems in the treatment of serious infectionsRobert P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
J Intensive Care Med 24:230-41. 2009..The newly approved carbapenem, doripenem, may help preserve the utility of the carbapenem class... - Ventilator-associated pneumonia patients who do not reduce bacteria from the lungs have a worse prognosisRobert P Baughman
University of Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
J Intensive Care Med 18:269-74. 2003..The inability to reduce the bacterial burden from the lower respiratory tract within the first few days of therapy for ventilator-associated pneumonia was associated with increased mortality... - Upper airway. 4: Sarcoidosis of the upper respiratory tract (SURT)Robert P Baughman
University of Cincinnati Medical Center, Cincinnati, Ohio, USA
Thorax 65:181-6. 2010..While corticosteroids are often the initial drug of choice, there have been several reports of the effectiveness of cytotoxic agents and anti-tumour necrosis factor antibodies... - SarcoidosisRobert P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267-0565, USA
Clin Dermatol 25:231. 2007 - Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluationRobert P Baughman
Internal Medicine, University of Cincinnati, University of Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
Chest 136:526-35. 2009..In a double-blind, randomized trial of infliximab for chronic pulmonary sarcoidosis, changes in serial chest roentgenograms were examined by radiologists, blinded to order or treatment... - Microbiologic diagnosis of ventilator-associated pneumoniaRobert P Baughman
University of Cincinnati Medical Center, 1001 Holmes, Eden Avenue, Cincinnati, OH 45627 0565, USA
Clin Chest Med 26:81-6. 2005..In addition, the clinician can be kept up to date about potential new pathogens as they occur in the intensive care unit. Knowledge of the local flora allows one to make a better choice of empiric therapy for VAP... - Novel therapies for sarcoidosisRobert P Baughman
Division of Pulmonary and Critical Care Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
Semin Respir Crit Care Med 28:128-33. 2007..This review focuses on these novel therapies for sarcoidosis, including indications for use, efficacy, toxicity, and monitoring... - Evidence-based therapy for cutaneous sarcoidosisRobert P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45220, USA
Clin Dermatol 25:334-40. 2007..This review will examine the conventional treatments of cutaneous sarcoidosis and focus on the best available evidence to make recommendations on treatment... - Six-minute walk test and health status assessment in sarcoidosisRobert P Baughman
Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45627, USA
Chest 132:207-13. 2007..The 6-min walk test has proved useful in assessing impairment and prognosis in various lung diseases... - Pulmonary hypertension in sarcoidosisRobert P Baughman
Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
Sarcoidosis Vasc Diffuse Lung Dis 23:108-16. 2006..Pulmonary hypertension has been notreported in some patients with sarcoidosis... - Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvementRobert P Baughman
University of Cincinnati Medical Center, Cincinnati, OH 45267, USA
Am J Respir Crit Care Med 174:795-802. 2006..Evidence suggests that tumor necrosis factor (TNF)-alpha plays an important role in the pathophysiology of sarcoidosis... - Presenting characteristics as predictors of duration of treatment in sarcoidosisR P Baughman
University of Cincinnati Medical Center, 1001 Holmes, Eden Avenue, Cincinnati, OH 45267 0565, USA
QJM 99:307-15. 2006..Some sarcoidosis patients never need therapy, but many still require therapy more than 2 years after initial diagnosis... - Six-minute walk test in managing and monitoring sarcoidosis patientsRobert P Baughman
University of Cincinnati Medical Center, Cincinnati, Ohio, USA
Curr Opin Pulm Med 13:439-44. 2007..To describe the value and limitations of using the 6-min test in assessing patients with sarcoidosis... - Technical aspects of bronchoalveolar lavage: recommendations for a standard procedureRobert P Baughman
Division of Pulmonary and Critical Care Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0565, USA
Semin Respir Crit Care Med 28:475-85. 2007..This article summarizes these recommendations and discusses the variable effects they have on BAL results. The final recommendations provide a standard methodology that can be used by the largest number of pulmonologists... - Fungal infections as a complication of therapy for sarcoidosisR P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
QJM 98:451-6. 2005..These agents may render the patient more susceptible to opportunistic infections. In addition, the fungal infection may be difficult to distinguish from the underlying sarcoidosis... - Tumour necrosis factor in sarcoidosis and its potential for targeted therapyRobert P Baughman
Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati Medical Center, Cincinnati, Ohio, USA
BioDrugs 17:425-31. 2003..However, as infliximab can be associated with reactivation of tuberculosis, which could be mistaken as worsening sarcoidosis, it should be used with caution in this patient group... - Diagnosis of ventilator-associated pneumoniaRobert P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, Ohio, USA
Curr Opin Crit Care 9:397-402. 2003..This review examines the various techniques used to diagnose ventilator-associated pneumonia. The ideal diagnostic test not only helps the clinician to recognize whether pneumonia is present, but also to influence clinical outcome... - Clinical characteristics of patients in a case control study of sarcoidosisR P Baughman
University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0565, USA
Am J Respir Crit Care Med 164:1885-9. 2001..3, p < 0.0001), bone marrow (chi(2) = 18.8, p < 0.001), and extrathoracic lymph node involvement (chi(2) = 7.21, p < 0.01). We conclude that the initial presentation of sarcoidosis is related to sex, race, and age... - Inhaled iloprost for sarcoidosis associated pulmonary hypertensionR P Baughman
Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
Sarcoidosis Vasc Diffuse Lung Dis 26:110-20. 2009..Patients with sarcoidosis associated pulmonary hypertension (SAPH) have responded to systemic prostacyclin therapy... - Combination therapy for sarcoidosisR P Baughman
Department of Medicine, University of Cincinnati Medical Center, 231 Albert Sabin Way, Room 6004, Cincinnati, OH 45267 0564, USA
Sarcoidosis Vasc Diffuse Lung Dis 18:133-7. 2001..Recently, the combination of cytotoxic and immune modifiers has been used for some cases of refractory sarcoidosis. The rationale use of combination therapy may enhance efficacy with reduced toxicity... - Infliximab for refractory sarcoidosisR P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, OH, USA
Sarcoidosis Vasc Diffuse Lung Dis 18:70-4. 2001..Infliximab is a chimeric monoclonal antibody which specifically inhibits TNF-alpha. We investigated the efficacy of infliximab for the therapy of chronic, resistant sarcoidosis... - Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systemsRobert P Baughman
University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
Am J Clin Dermatol 9:155-61. 2008..Facial lesions including lupus pernio are often a form of chronic cutaneous sarcoidosis... - Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosisR P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, OH 45267 0564, USA
Sarcoidosis Vasc Diffuse Lung Dis 16:57-61. 1999..In order to validate this mouse as a model for idiopathic pulmonary fibrosis in humans, we studied the expression of TGF-alpha in lung tissue of patients with idiopathic pulmonary fibrosis compared to control lung tissue... - The lung in the immunocompromised patient. Infectious complications Part 1R P Baughman
Division of Pulmonary and Critical Care Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0564, USA
Respiration 66:95-109. 1999..In this review, we will discuss these various possible infections, their frequency of occurrence, and their clinical presentation in the various immunosuppressed groups... - Methotrexate for sarcoidosisR P Baughman
Department of Medicine, University of Cincinnati Medical Center, Ohio 45267 0564, USA
Sarcoidosis Vasc Diffuse Lung Dis 15:147-9. 1998..Long term use of the drug is associated with some toxicity. Liver biopsies have proved a useful way of identifying which patients may remain on therapy... - Diagnostic strategies in Pneumocystis carinii pneumoniaR P Baughman
University of Cincinnati Medical Center, PO Box 670564, Cincinnati, OH 45267 0564, USA
Front Biosci 3:e1-12. 1998..In addition, the polymerase chain reaction (PCR) is successfully being used in the diagnosis of P. carinii. Overall, these techniques allow the clinician to tailor the diagnostic testing for the individual patient... - Surfactant replacement for ventilator-associated pneumonia: a preliminary reportRobert P Baughman
Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267 0564, USA
Respiration 69:57-62. 2002..Surfactant abnormalities have been described in bacterial pneumonia... - Thalidomide for chronic sarcoidosisRobert P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
Chest 122:227-32. 2002..Lupus pernio is a skin manifestation of sarcoidosis that does not remit spontaneously, and was used as a marker of efficacy of thalidomide for sarcoidosis... - Therapeutic options for sarcoidosis: new and oldRobert P Baughman
University of Cincinnati Medical Center, Interstitial Lung Disease and Sarcoidosis Clinic, Cincinnati, Ohio 45267 0565, USA
Curr Opin Pulm Med 8:464-9. 2002..A key cytokine in chronic sarcoidosis appears to be tumor necrosis factor. Drugs that inhibit its release or block its effect have been reported as effective for sarcoidosis... - Nonbronchoscopic evaluation of ventilator-associated pneumoniaRobert P Baughman
Interstitial Lung Disease and Sarcoidosis Center, Department of Internal Medicine, University of Cincinnati Medical Center, 1001 Holmes Hospital, Eden Avenue and Albert Sabin Way, Cincinnati, OH 45267 0565, USA
Semin Respir Infect 18:95-102. 2003..By using this approach, the physician should be able to better direct therapy and reduce mortality from pneumonia in the intensive care unit (ICU)... - Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluationRobert P Baughman
Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
Chest 138:1078-85. 2010..Our objective was to determine if the cause of PH affects survival in patients with sarcoidosis with persistent dyspnea... - SarcoidosisRobert P Baughman
Department of Internal Medicine, University of Cincinnati, Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
Lancet 361:1111-8. 2003..New agents, including pentoxifylline, thalidomide, and infliximab have proved useful in selected cases. The effectiveness of these agents seems to lie in their ability to block TNF, especially in the treatment of chronic disease... - Ocular sarcoidosisRobert P Baughman
Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267 0565, USA
Semin Respir Crit Care Med 31:452-62. 2010..Recent reports have demonstrated that monoclonal antibodies blocking tumor necrosis factor can be quite effective for chronic refractory ocular sarcoidosis... - Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosisRobert P Baughman
Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA
Arch Intern Med 163:615-20. 2003..Because sarcoidosis has a high frequency of liver involvement, we routinely perform a liver biopsy after each cumulative gram of methotrexate therapy in patients with sarcoidosis in whom we plan to continue therapy... - A concise review of pulmonary sarcoidosisRobert P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, Ohio, USA
Am J Respir Crit Care Med 183:573-81. 2011..There have been several recent studies demonstrating treatment options for these problems... - Therapy for sarcoidosis: evidence-based recommendationsRobert P Baughman
Interstitial Lung Disease and Sarcoidosis Clinic, Department of Medicine, University of Cincinnati, Cincinatti, OH 45267, USA
Expert Rev Clin Immunol 8:95-103. 2012..In addition, new agents have proved to be useful for patients with refractory disease... - Use of fluticasone in acute symptomatic pulmonary sarcoidosisRobert P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, OH 45267 0565, USA
Sarcoidosis Vasc Diffuse Lung Dis 19:198-204. 2002..Inhaled corticosteroids have been used with variable success in sarcoidosis. The role of the inhaled corticosteroid fluticasone in symptomatic pulmonary patients was studied... - Can persistent tumor necrosis factor release lead to refractory sarcoidosis?Robert P Baughman
Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati Medical Center, OH 45267 0565, USA
Sarcoidosis Vasc Diffuse Lung Dis 19:164-6. 2002 - Nonsteroidal therapy for idiopathic pulmonary fibrosisR P Baughman
Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati Medical Center, Eden Avenue and Albert Sabin Way, Cincinnati, OH 45267 0565, USA
Curr Opin Pulm Med 7:309-13. 2001..The future therapy of interstitial lung disease probably will consist of multiple agents aimed at several aspects of the inflammatory reaction of interstitial lung disease... - Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trialM A Judson
Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC, USA
Eur Respir J 31:1189-96. 2008..Infliximab may be beneficial compared with placebo in the treatment of extrapulmonary sarcoidosis in patients already receiving corticosteroids, as assessed by the severity tool described in the present study... - Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigueElyse E Lower
Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
Chest 133:1189-95. 2008..Fatigue is a common complaint in patients with sarcoidosis. We studied the effectiveness of dexmethylphenidate hydrochloride (d-MPH) in treating sarcoidosis-associated fatigue... - Difficult treatment issues in sarcoidosisR P Baughman
Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati, Cincinnati, OH 45267 0564, USA
J Intern Med 253:41-5. 2003..For these patients, new agents such as thalidomide and the monoclonal antibodies to tumour necrosis factor have been occasionally helpful. This paper reviews several important issues in the management of sarcoidosis... - Role of bronchoalveolar lavage in interstitial lung diseaseR P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio, USA
Clin Chest Med 22:331-41. 2001..Although rarely diagnostic, it is often supportive. In conjunction with high-resolution CT scan, most patients with ILD can be diagnosed using relatively noninvasive methods... - Surfactant protein deficiency in familial interstitial lung diseaseR S Amin
Children s Hospital Medical Center, Department of Pediatrics, Cincinnati, Ohio 45229 3039, USA
J Pediatr 139:85-92. 2001..To determine the contribution of surfactant protein abnormalities to the development of chronic lung injury in a familial form of interstitial lung disease... - Managing serious infections in the hospital: a new modelR P Baughman
Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA
Clin Microbiol Infect 11:1-3. 2005 - Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task ForceR P Baughman
University of Cincinnati Medical Center, Cincinnati, OH, USA
Sarcoidosis Vasc Diffuse Lung Dis 28:56-64. 2011..Sarcoidosis patients who were African American or older were likely to have a higher COS, indicating more chronic disease. The COS may be useful in future studies of sarcoidosis... - The diagnostic pathway to sarcoidosisMarc A Judson
Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston 29425, USA
Chest 123:406-12. 2003..To examine the time from the first physician visit to the diagnosis of sarcoidosis... - Breast disease in sarcoidosisE E Lower
University of Cincinnati Medical Center, Department of Medicine, Ohio 45267-0562, USA
Sarcoidosis Vasc Diffuse Lung Dis 18:301-6. 2001..Because physical examination and mammography findings are unable to distinguish between sarcoidosis and malignancy, biopsy of all suspicious lesions in sarcoidosis is recommended... - Two year prognosis of sarcoidosis: the ACCESS experienceMarc A Judson
Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA
Sarcoidosis Vasc Diffuse Lung Dis 20:204-11. 2003..Several factors associated with improved or worse outcome over two years were identified... - Treatment of sarcoidosisRobert P Baughman
Department of Medicine, University of Cincinnati Medical Center, Eden Avenue, Cincinnati, OH 45267 0565, USA
Clin Chest Med 29:533-48, ix-x. 2008..The tumor necrosis factor antibody infliximab has proved useful in treating refractory sarcoidosis. These various agents led to a treatment strategy for the various aspects of sarcoidosis... - Diagnosis and management of spinal cord sarcoidosisDeborah A Bradley
Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267-0565, USA
Sarcoidosis Vasc Diffuse Lung Dis 23:58-65. 2006..Prompt treatment is important in long term outcome. Cyclophosphamide was an effective, well tolerated corticosteroid-sparing agent for patients with spinal cord sarcoidosis... - Pulmonary hypertension associated with sarcoidosisRobert P Baughman
Department of Internal Medicine, Interstitial Lung Disease and Sarcoidosis Clinic, University of Cincinnati Medical Center, Holmes Eden Ave, Cincinnati, Ohio 45267, USA
Arthritis Res Ther 9:S8. 2007..Such therapy possibly could be combined with standard anti-inflammatory agents to improve outcome... - Antibiotic resistance in the intensive care unitRobert P Baughman
University of Cincinnati Medical Center, Holmes Hospital, Cincinnati, OH 45267, USA
Curr Opin Crit Care 8:430-4. 2002..General strategies for reducing antibiotic resistance, on the other hand, include varying the agents used in the ICU over time. Reduction of the duration of therapy may prove to be another method of reducing antibiotic resistance... - Preface. SarcoidosisRobert P Baughman
Department of Medicine, University of Cincinnati Medical Center, Eden Avenue, Cincinnati, OH 45267-0565, USA
Clin Chest Med 29:xiii-xiv. 2008 - Factors influencing the production of wheezes during expiratory maneuvers in normal subjectsY Ploysongsang
Department of Internal Medicine, University of Cincinnati College of Medicine, Ohio
Respiration 54:50-60. 1988..This was achieved by either an increase in the driving critical pleural pressure or narrowing of bronchi by a larger compressing pleural pressure or smaller lung volumes... - Sterols of Pneumocystis carinii hominis organisms isolated from human lungsE S Kaneshiro
Department of Biological Sciences, University of Cincinnati, Cincinnati, Ohio 45221, USA
Clin Diagn Lab Immunol 6:970-6. 1999..g., fungisterol and methylcholest-7-ene-3beta-ol) previously identified in P. carinii carinii were also present in organisms isolated from human specimens. Pneumocysterol was detected in only some of the samples... - Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes--proceedings of the HCAP SummitMarin H Kollef
Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
Clin Infect Dis 46:S296-334; quiz 335-8. 2008..The results were then compared with results of the same survey as completed by 744 Infectious Diseases Society of America members. The similarities and differences between those survey results are the basis of this publication... - HLA and environmental interactions in sarcoidosisM D Rossman
Division of Pulmonary, Allergy and Critical Care, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104 6160, USA
Sarcoidosis Vasc Diffuse Lung Dis 25:125-32. 2008..Future studies in defined phenotypes of sarcoidosis may be necessary to define environmental and genetic associations with sarcoidosis... - Rheumatologic manifestations of sarcoidosisNadera J Sweiss
Section of Rheumatology, Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637, USA
Semin Respir Crit Care Med 31:463-73. 2010..We present two cases of sarcoidosis with rheumatologic manifestations. Our intent is to encourage a multidisciplinary, translational approach to meet the challenges and difficulties in understanding and treating sarcoidosis... - Pulmonary hypertension in neurofibromatosisPeter J Engel
The Ohio Heart and Vascular Center, Cincinnati, Ohio, USA
Am J Cardiol 99:1177-8. 2007..The published research is reviewed. In conclusion, it is suggested that the association between these conditions be recognized in the classification of pulmonary hypertension... - Treatment of right ventricular dysfunction in pulmonary arterial hypertension: theoretical considerationsPeter J Engel
Pulmonary Hypertension Clinic, The Christ Hospital, Cincinnati, OH, USA
Med Hypotheses 73:448-52. 2009..This is a hypothesis which could be tested in an animal model of this condition... - Bronchoalveolar cellular analysis in scleroderma lung disease: does Sutton's law hold?Robert P Baughman
Am J Respir Crit Care Med 177:2-3. 2008 - A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosisMilton D Rossman
Hospital of the University of Pennsylvania, Philadelphia, PA, USA
Sarcoidosis Vasc Diffuse Lung Dis 23:201-8. 2006..CONCLUSIONS: Infliximab may improve VC in patients with active PS resistant to steroids. Larger scale, longer term studies will be needed to assess both safety and efficacy... - Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future conceptsNadera J Sweiss
Section of Rheumatology and Immunology, University of Chicago, Chicago, IL 60637, USA
Clin Dermatol 25:341-6. 2007..The long-term safety and efficacy of such therapies are yet to be determined in well-designed clinical trials with long-term follow-up... - Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon?Nadera J Sweiss
J Rheumatol 34:2129-31. 2007 - Systemic evaluation of a potential cutaneous sarcoidosis patientUlrich Costabel
Department of Pneumology Allergy, Ruhrlandklinik Essen, D 45239 Essen, Germany
Clin Dermatol 25:303-11. 2007..The evaluation leads to a wide number of organs being assessed by either history, physical examination or routine laboratory investigations. The major organs routinely assessed are the lungs, the eyes, the liver and the heart... - The variability of sarcoidosis: can we predict it?Robert P Baughman
Chest 123:1329-32. 2003 - Pulmonary and psychosocial findings at enrollment in the ACCESS studyHenry Yeager
Pulmonary, Critical Care, and Sleep Medicine, Georgetown University Medical Center, Washington, DC 20057, USA
Sarcoidosis Vasc Diffuse Lung Dis 22:147-53. 2005..To assess lung involvement and the association of demographic and psychosocial factors with respiratory health in 736 persons with sarcoidosis at enrollment in A Case Control Etiologic Study of Sarcoidosis (ACCESS)... - Nosocomial pneumonia: the gorilla in the ICURobert P Baughman
J Intensive Care Med 18:227-8. 2003 - Reverse phenotyping in sarcoidosisMichael C Iannuzzi
Am J Respir Crit Care Med 175:4-5. 2007 - A case control etiologic study of sarcoidosis: environmental and occupational risk factorsLee S Newman
National Jewish Medical and Research Center and Univresity of Colorado Health Scienes Center, Denver, CO 80206, USA
Am J Respir Crit Care Med 170:1324-30. 2004..65, CI 0.51-0.82). The study did not identify a single, predominant cause of sarcoidosis. We identified several exposures associated with sarcoidosis risk, including insecticides, agricultural employment, and microbial bioaerosols... - Comparison of sarcoidosis phenotypes among affected African-American siblingsMarc A Judson
Division of Pulmonary and Critical Care Medicine CSB 812, Medical University of South Carolina, Charleston, SC 29425, USA
Chest 130:855-62. 2006..To test the hypothesis that sibling pairs, who share genes and environmental exposures, might have similar phenotypic expressions of sarcoidosis beyond what would be expected by chance alone... - Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS)Juliana Barnard
Division of Environmental and Occupational Health Sciences, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
J Occup Environ Med 47:226-34. 2005..To determine whether specific occupations and industries may be associated with sarcoidosis... - A sarcoidosis genetic linkage consortium: the sarcoidosis genetic analysis (SAGA) studyBenjamin A Rybicki
Department of Biostatistics and Research Epidemiology, Henry Ford Health System, Detroit, MI 48202, USA
Sarcoidosis Vasc Diffuse Lung Dis 22:115-22. 2005..In the United States of America, African Americans have a higher sarcoidosis incidence and suffer greater morbidity than Caucasians... - The spectrum of biopsy sites for the diagnosis of sarcoidosisAlvin S Teirstein
Mount Sinai Medical Center, New York, NY 10029, USA
Sarcoidosis Vasc Diffuse Lung Dis 22:139-46. 2005..Clinicians must decide which site offers the best chance of achieving a diagnostic biopsy with the least patient risk and discomfort... - Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactantRoger G Spragg
Veteran s Administration Medical Center, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
Am J Respir Crit Care Med 167:1562-6. 2003..The presence of exogenous surfactant was not detected in lavage fluid obtained at 120 hours. Future studies might rationally employ larger surfactant doses and a more prolonged dosing schedule...